Journal Article

Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients

M. Oette, M. Kurowski, T. Feldt, A. Kroidl, A. Sagir, C. Vogt, M. Wettstein and D. Häussinger

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 2, pages 416-419
Published in print August 2005 | ISSN: 0305-7453
Published online June 2005 | e-ISSN: 1460-2091 | DOI: https://dx.doi.org/10.1093/jac/dki234
Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients

Show Summary Details

Preview

Objectives: The insulin-sensitizer rosiglitazone is under investigation for therapy of HIV-associated lipodystrophy syndrome (LDS). Little is known about pharmacological interactions with antiretroviral (ARV) drugs.

Methods: Therapeutic drug monitoring (TDM) of ARV drugs was performed in a prospective study before and at day 28 after start of treatment with 4 mg of rosiglitazone for combined LDS. Drug levels were measured in the morning fasting, and 0.5, 1, 2, 4, 6 and 8 h after standardized drug intake. Values were log-transformed for analysis.

Results: Twelve males and six females were assessed; mean age was 50.7 years and mean CD4 cell count was 496 cells/mm3. All patients had a viral load below 50 copies/mL, and backbone ARV therapy consisted of two or three nucleoside reverse transcriptase inhibitors in all cases. After administration of rosiglitazone, no significant differences in Cmax, Cmin and AUC were found in cases treated with efavirenz (n = 10) and lopinavir (n = 4). Mean Cmax of nevirapine (n = 4) was reduced significantly [−0.44; 95% confidence interval (CI) −0.86 to −0.01]. Furthermore, there was a consistent trend to a reduction in the geometric mean ratio (GMR) of Cmax, Cmin and AUC (GMR of Cmax 0.95; 95% CI 0.9–1.0; GMR of Cmin 0.89; 95% CI 0.65–1.13; GMR of AUC 0.96; 95% CI 0.91–1.01).

Conclusions: Treatment with 4 mg of rosiglitazone for HIV-associated LDS is likely to reduce the bioavailability of nevirapine. Thus, routine TDM is recommended for patients treated with rosiglitazone and nevirapine. A therapy consisting of efavirenz or lopinavir seems to be without negative impact. Further studies on the interaction of rosiglitazone with ARV drugs are necessary.

Keywords: HAART; therapeutic drug monitoring; glitazones; drug interactions

Journal Article.  1923 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.